Skip to main content
AmigoFish

At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2

From BiotechTV - News · · 22 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.

Back to BiotechTV - News · Report a problem